Small molecular ICG in free form has a short circulation half‐life (3‐4 min) and lacks tumor selectivity.[35, 36] However, taking advantage of the tumor‐targeting capability of ICAM1 monoclonal antibody, we designed and synthesized an ICAM1 antibody‐bound ICG (ICAM1‐ICG, Figure2A) by covalently conjugating ICG‐NHS ester with the amine groups of lysine in the ICAM1 antibody. Here, ICAM1 is linked to neoplasm.